Clostridium difficile

Current Opinion in Infectious Diseases

Volumn 15, Issue 5, 2002, Pages 513-518

  Stoddart, Bethan ^a   Wilcox, Mark H ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN; CLARITHROMYCIN; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CLOSTRIDIUM TOXIN; CYTOTOXIN; GT 160246; METRONIDAZOLE; PENICILLIN DERIVATIVE; POLYMER; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOXOID; UNCLASSIFIED DRUG; VANCOMYCIN; BACTERIAL TOXIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; DIARRHEA; DISEASE PREDISPOSITION; HUMAN; IMMUNIZATION; IMMUNOASSAY; IMMUNOGENICITY; INFECTION RISK; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; LACTOBACILLUS; NONHUMAN; PATHOGENICITY; REVIEW; SACCHAROMYCES BOULARDII; MICROBIOLOGY; PSEUDOMEMBRANOUS COLITIS;

BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS;

EID: 0036791290     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200210000-00010     Document Type: Review

References (51)

1. Kyne L, Hamel MB, Polavaram R, Kelly CP, Health care costs and mortality associated with nosocomial diarrhoea due to Clostridium difficile. Clin Infect Dis 2002; 34:346-353.
2. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235:363-372.
3. Sakurai T, Hajiro K, Takakuwa H, et al. Liver abscess caused by Clostridium difficile. Scand J Infect Dis 2001; 33:69-70.
4. Freiler JF, Durning SJ, Ender PT. Clostridium difficile small bowel enteritis occurring after total colectomy. Clin Infect Dis 2001; 33:1429-1431.
5. Jacobs A, Barnard K, Fishel R, Gradon JD. Extracolonic manifestations of Clostridium difficile infections. Presentation of 2 cases and review of the literature. Medicine (Baltimore) 2001; 80:88-101.
6. Garcia-Lechuz JM, Hernangomez S, Juan RS, et al. Extra-intestinal infections caused by Clostridium difficile. Clin Microbiol Infect 2001; 7:453-457.
7. Kamaras J, Murrell WG. The effect of bacterial enterotoxins implicated in SIDS on the rabbit intestine. Pathology 2001; 33:187-196.
8. Gorschluter M, Glasmacher A, Hahn C, et al. Clostridium difficile infection in patients with neutropenia. Clin Infect Dis 2001; 33:786-791.
9. Yamazawa K, Kanno H, Seki K, et al. Life-threatening Clostridium difficile-associated diarrhea induced by paclitaxel-carboplatin combination chemotherapy. Acta Obstet Gynecol Scand 2001; 80:768-769.
10. Wistrom J, Norrby SR, Myhre EB, et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother 2001; 47:43-50.
11. Harbarth S, Samore MH, Carmeli Y. Antibiotic prophylaxis and the risk of Clostridium difficile-associated diarrhoea. J Hosp Infect 2001; 48:93-97.
12. Alonso R, Pelaez T, Gonzalez-Abad MJ, et al. In vitro activity of new quinolones against Clostridium difficile. J Antimicrob Chemother 2001; 47:195-197.
13. Wilcox MH. Clarithromycin and risk of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 2001; 47:358-359.
14. Harsch IA, Hahn EG, Konturek PC. Pseudomembranous colitis after eradication of Helicobacter pylori infection with a triple therapy. Med Sci Monit 2001; 7:751-754.
15. Ozawa TT, Valadez T. Clostridium difficile infection associated with levofloxacin treatment. Tenn Med 2002; 95:113-115.
16. Yip C, Loeb M, Salama S, et al. Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol 2001; 22:572-575.
17. Ackermann G, Tang YJ, Kueper R, et al. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA. Antimicrob Agents Chemother 2001; 45:2348-2353.
18. Spigaglia P, Cardines R, Rossi S, et al. Molecular typing and long-term comparison of clostridium difficile strains by pulsed-field gel electrophoresis and PCR-ribotyping. J Med Microbiol 2001 50:407-414.
19. Rupnik M, Brazier JS, Duerden BI, et al. Comparison of toxinotyping and PCR ribotyping of Clostridium difficile strains and description of novel toxinotypes. Microbiology 2001; 147 (Pt 2):439-447.
20. Klaassen CH, van Haren HA, Horrevorts AM. Molecular fingerprinting of Clostridium difficile isolates: pulsed-field gel electrophoresis versus amplified fragment length polymorphism. J Clin Microbiol 2002; 40:101-104.
21. Pituch H, van den Braak N, van Leeuwen W, et al. Clonal dissemination of a toxin-A-negative/toxin-B-positive Clostridium difficile strain from patients with antibiotic-associated diarrhoea in Poland. Clin Microbiol Infect 2001; 7:442-446.
22. Verity P, Wilcox MH, Fawley W, Parnell P. Prospective evaluation of environmental contamination by Clostridium difficile in isolation side rooms. J Hosp Infect 2001; 49:204-209.
23. Fawley WN, Wilcox MH. Molecular epidemiology of endemic Clostridium difficile infection. Epidemiol Infect 2001; 126:343-350.
24. Perry C, Marshall R, Jones E. Bacterial contamination of uniforms. J Hosp Infect 2001; 48:238-241.
25. Starr JM, Campbell A. Mathematical modeling of Clostridium difficile infection. Olin Microbiol Infect 2001; 7:432-437.
26. Kirkpatrick ID, Greenberg HM. Evaluating the CT diagnosis of Clostridium difficile colitis: should CT guide therapy? AJR Am J Roentgenol 2001; 176:635-639.
27. Vanpoucke H, De Baere T, Claeys G, et al. Evaluation of six commercial assays for the rapid detection of Clostridium difficile toxin and/or antigen in stool specimens. Clin Microbiol Infect 2001; 7:55-64.
28. Landry ML, Topal J, Ferguson D, et al. Evaluation of biosite triage Clostridium difficile panel for rapid detection of Clostridium difficile in stool samples. J Clin Microbiol 2001; 39:1855-1858.
29. Lozniewski A, Rabaud C, Dotto E, et al. Laboratory diagnosis of Clostridium difficile-associated diarrhea and colitis: usefulness of Premier Cytoclone A+B enzyme immunoassay for combined detection of stool toxins and toxigenic C.difficile strains. J Clin Microbiol 2001; 39:1996-1998.
30. O'Connor D, Hynes P, Cormican M, et al. Evaluation of methods for detection of toxins in specimens of feces submitted for diagnosis of Clostridium difficile-associated diarrhoea, J Clin Microbiol 2001; 39:2846-2849.
31. Patel JB, Donahue AM, Nachamkin I. Performance of two rapid, single-use immunoassays for the detection of Clostridium difficile toxin A. Diagn Microbiol Infect Dis 2001; 39:21-24.
32. Limaye A, Turgeon D, Cookson B, Fritsche T. Pseudomembranous colitis caused by a toxin A-B+ strain of Clostridium difficile. J Clin Microbiol 2000; 36:1696-1697.
33. Johnson S, Kent SA, O'Leary KJ, et al. Fatal pseudomembranous colitis associated with a variant Clostridium difficile strain not detected by toxin A immunoassay. Ann Intern Med 2001; 135:434-438.
34. Bouza E, Pelaez T, Alonso R, et al. "Second-look" cytotoxicity: an evaluation of culture plus cytotoxin assay of Clostridium difficile isolates in the laboratory diagnosis of CDAD. J Hosp Infect 2001; 48:233-237.
35. Drudy D, O'Donoghue DP, Baird A, et al. Flow cytometric analysis of Clostridium difficile adherence to human intestinal epithelial cells. J Med Microbiol 2001; 50:526-534.
36. Hennequin C, Porcheray F, Waligora-Dupriet A, et al. GroEL (Hsp60) of Clostridium difficile is involved in cell adherence. Microbiology 2001; 147 (Pt 1):87-96.
37. Waligora AJ, Hennequin C, Mullany P, et al. Characterization of a cell surface protein of Clostridium difficile with adhesive properties. Infect Immun 2001; 69:2144-2153.
38. Tasteyre A, Barc MC, Collignon A. et al. Role of FliC and FliD flagellar proteins of Clostridium difficile in adherence and gut colonization. Infect Immun 2001; 69:7937-7940.
39. Tasteyre A, Karjalainen T, Avesani V, et al. Molecular characterization of fliD gene encoding flagellar cap and its expression among Clostridium difficile isolates from different serogroups. J Clin Microbiol 2001; 39:1178-1183.
40. Poxton IR, McCoubrey J, Blair G. The pathogenicity of Clostridium difficile. Clin Microbiol Infect 2001; 7:421-427.
41. Nusrat A, Von Eichel-Streiber C, Turner JR, et al. Clostridium difficile toxins disrupt epithelial barrier function by altering membrane microdomain localization of tight junction proteins. Infect Immun 2001; 69:1329-1336.
42. Tan KS, Wee BY, Song KP. Evidence for holin function of tcdE gene in the pathogenicity of Clostridium difficile. J Med Microbiol 2001; 50:613-619.
43. Friedenberg F, Fernandez A, Kaul V, et al. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum 2001; 44:1176-1180.
44. Brazier J, Fawley W, Freeman J, Wilcox M. Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother 2001; 48:741-742.
45. Shetler K, Nieuwenhuis R, Wren SM, Triadafilopoulos G. Decompressive colonoscopy with intracolonic vancomycin administration for the treatment of severe pseudomembranous colitis. Surg Endosc 2001; 15:653-659.
46. Nathanson DR, Sheahan M, Chao L, Wallack MK. Intracolonic use of vancomycin for treatment of Clostridium difficile colitis in a patient with a diverted colon: report of a case. Dis Colon Rectum 2001; 44:1871-1872.
47. Thomas MR, Litin SC, Osmon DR, et al. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Mayo Clin Proc 2001; 76:883-889.
48. Qamar A, Aboudola S, Warny M, et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 2001; 69:2762-2765.
49. Kurtz CB, Cannon EP, Brezzani A, et al. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother 2001; 45:2340-2347.
50. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357:189-193.
51. Kotloff KL, Wasserman SS, Losonsky GA, et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001; 69:988-995.